Lyve-1 deficiency enhances the hepatic immune microenvironment entailing altered susceptibility to melanoma liver metastasis.
Immune microenvironment
Liver
Liver homeostasis
Liver metastasis
Lyve-1
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
10 Dec 2022
10 Dec 2022
Historique:
received:
31
08
2022
accepted:
21
11
2022
entrez:
10
12
2022
pubmed:
11
12
2022
medline:
11
12
2022
Statut:
epublish
Résumé
Hyaluronan receptor LYVE-1 is expressed by liver sinusoidal endothelial cells (LSEC), lymphatic endothelial cells and specialized macrophages. Besides binding to hyaluronan, LYVE-1 can mediate adhesion of leukocytes and cancer cells to endothelial cells. Here, we assessed the impact of LYVE-1 on physiological liver functions and metastasis. Mice with deficiency of Lyve-1 (Lyve-1-KO) were analyzed using histology, immunofluorescence, microarray analysis, plasma proteomics and flow cytometry. Liver metastasis was studied by intrasplenic/intravenous injection of melanoma (B16F10 luc2, WT31) or colorectal carcinoma (MC38). Hepatic architecture, liver size, endothelial differentiation and angiocrine functions were unaltered in Lyve-1-KO. Hyaluronan plasma levels were significantly increased in Lyve-1-KO. Besides, plasma proteomics revealed increased carbonic anhydrase-2 and decreased FXIIIA. Furthermore, gene expression analysis of LSEC indicated regulation of immunological pathways. Therefore, liver metastasis of highly and weakly immunogenic tumors, i.e. melanoma and colorectal carcinoma (CRC), was analyzed. Hepatic metastasis of B16F10 luc2 and WT31 melanoma cells, but not MC38 CRC cells, was significantly reduced in Lyve-1-KO mice. In vivo retention assays with B16F10 luc2 cells were unaltered between Lyve-1-KO and control mice. However, in tumor-free Lyve-1-KO livers numbers of hepatic CD4 Lyve-1 deficiency controlled hepatic metastasis in a tumor cell-specific manner leading to reduced growth of hepatic metastases of melanoma, but not CRC. Anti-tumorigenic effects are likely due to enhancement of the premetastatic hepatic immune microenvironment influencing early liver metastasis formation.
Sections du résumé
BACKGROUND
BACKGROUND
Hyaluronan receptor LYVE-1 is expressed by liver sinusoidal endothelial cells (LSEC), lymphatic endothelial cells and specialized macrophages. Besides binding to hyaluronan, LYVE-1 can mediate adhesion of leukocytes and cancer cells to endothelial cells. Here, we assessed the impact of LYVE-1 on physiological liver functions and metastasis.
METHODS
METHODS
Mice with deficiency of Lyve-1 (Lyve-1-KO) were analyzed using histology, immunofluorescence, microarray analysis, plasma proteomics and flow cytometry. Liver metastasis was studied by intrasplenic/intravenous injection of melanoma (B16F10 luc2, WT31) or colorectal carcinoma (MC38).
RESULTS
RESULTS
Hepatic architecture, liver size, endothelial differentiation and angiocrine functions were unaltered in Lyve-1-KO. Hyaluronan plasma levels were significantly increased in Lyve-1-KO. Besides, plasma proteomics revealed increased carbonic anhydrase-2 and decreased FXIIIA. Furthermore, gene expression analysis of LSEC indicated regulation of immunological pathways. Therefore, liver metastasis of highly and weakly immunogenic tumors, i.e. melanoma and colorectal carcinoma (CRC), was analyzed. Hepatic metastasis of B16F10 luc2 and WT31 melanoma cells, but not MC38 CRC cells, was significantly reduced in Lyve-1-KO mice. In vivo retention assays with B16F10 luc2 cells were unaltered between Lyve-1-KO and control mice. However, in tumor-free Lyve-1-KO livers numbers of hepatic CD4
CONCLUSION
CONCLUSIONS
Lyve-1 deficiency controlled hepatic metastasis in a tumor cell-specific manner leading to reduced growth of hepatic metastases of melanoma, but not CRC. Anti-tumorigenic effects are likely due to enhancement of the premetastatic hepatic immune microenvironment influencing early liver metastasis formation.
Identifiants
pubmed: 36496412
doi: 10.1186/s12935-022-02800-x
pii: 10.1186/s12935-022-02800-x
pmc: PMC9741792
doi:
Types de publication
Journal Article
Langues
eng
Pagination
398Subventions
Organisme : Deutsche Stiftung Dermatologie e.V. (Deutsche Dermatologische Gesellschaft e.V. (DDG)/Arbeitsgemeinschaft Dermatologische Forschung e.V. (ADF)), Germany
ID : Clinician Scientist Program
Organisme : Deutsche Forschungsgemeinschaft
ID : SPP1937 (CE 140-2.2)
Organisme : Deutsche Forschungsgemeinschaft
ID : SPP1937 (CE 140-2.2)
Organisme : Deutsche Forschungsgemeinschaft
ID : 394046768
Organisme : Deutsche Forschungsgemeinschaft
ID : 394046768
Organisme : Deutsche Forschungsgemeinschaft
ID : 394046768
Informations de copyright
© 2022. The Author(s).
Références
Immunity. 2016 Mar 15;44(3):492-504
pubmed: 26982356
Am J Physiol Gastrointest Liver Physiol. 2016 Aug 1;311(2):G246-51
pubmed: 27288423
Dev Dyn. 2008 Jul;237(7):1901-9
pubmed: 18570254
Cancer Sci. 2018 Oct;109(10):3171-3182
pubmed: 30058195
J Clin Invest. 2017 Mar 1;127(3):1099-1114
pubmed: 28218627
Gut. 2013 Aug;62(8):1169-78
pubmed: 22637699
Nat Med. 2016 Aug;22(8):945-51
pubmed: 27428900
J Hepatol. 2021 Feb;74(2):380-393
pubmed: 32916216
Hepatology. 2018 Aug;68(2):707-722
pubmed: 29059455
JAMA Oncol. 2018 Oct 1;4(10):1382-1388
pubmed: 30073321
Ann Surg Oncol. 2009 Sep;16(9):2524-30
pubmed: 19568816
iScience. 2021 Jan 05;24(2):102032
pubmed: 33521599
FEBS Lett. 2006 Nov 13;580(26):6259-68
pubmed: 17070806
Cancer Res. 2002 Oct 1;62(19):5393-8
pubmed: 12359742
Nat Rev Gastroenterol Hepatol. 2018 Sep;15(9):555-567
pubmed: 29844586
Front Immunol. 2017 Nov 08;8:1479
pubmed: 29167669
Cancer Res. 2001 Nov 15;61(22):8079-84
pubmed: 11719431
Nat Immunol. 2017 Jul;18(7):762-770
pubmed: 28504698
Blood. 2017 Jan 26;129(4):405-414
pubmed: 27864295
Hepatology. 2010 Jun;51(6):2172-82
pubmed: 20513002
Am J Pathol. 2020 Feb;190(2):358-371
pubmed: 31783007
Blood. 2012 Aug 30;120(9):1899-907
pubmed: 22797697
J Pathol. 2006 May;209(1):67-77
pubmed: 16482496
J Clin Invest. 2011 Mar;121(3):985-97
pubmed: 21317534
Blood. 2017 Jan 26;129(4):415-419
pubmed: 27903529
Angiogenesis. 2021 May;24(2):289-310
pubmed: 33745018
Clin Cancer Res. 2016 Dec 15;22(24):5971-5982
pubmed: 27797969
J Biol Chem. 2001 Jun 1;276(22):19420-30
pubmed: 11278811
Nat Commun. 2011 Nov 22;2:555
pubmed: 22109529
Oncol Lett. 2017 Oct;14(4):3883-3892
pubmed: 28943897
Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4263-8
pubmed: 22371575
J Cell Biol. 1999 Feb 22;144(4):789-801
pubmed: 10037799
J Clin Invest. 2011 Feb;121(2):703-14
pubmed: 21293057
Nat Med. 2021 Jan;27(1):152-164
pubmed: 33398162
Biomed Res. 2014;35(1):37-45
pubmed: 24573200
Nat Nanotechnol. 2016 Nov;11(11):986-994
pubmed: 27668795
Melanoma Res. 2017 Aug;27(4):300-308
pubmed: 28445180
Blood. 2011 Aug 18;118(7):1912-22
pubmed: 21705499
Cancer Res. 2019 Feb 1;79(3):598-610
pubmed: 30530502
Science. 2017 Aug 25;357(6353):
pubmed: 28775214
Mol Cell Biol. 2007 Jan;27(2):595-604
pubmed: 17101772
Nature. 2010 Nov 11;468(7321):310-5
pubmed: 21068842
Cancer Res. 2017 Jul 1;77(13):3431-3441
pubmed: 28536280
J Cell Physiol. 2009 May;219(2):430-7
pubmed: 19170073
Matrix Biol. 2019 May;78-79:219-235
pubmed: 29425695
Biomed Res. 2016;37(3):187-98
pubmed: 27356606
J Transl Med. 2022 Feb 2;20(1):62
pubmed: 35109875
Gene. 2021 Feb 5;768:145284
pubmed: 33130055
Front Oncol. 2021 Jun 02;11:672660
pubmed: 34150638
PLoS One. 2013 May 22;8(5):e63463
pubmed: 23717428